lack of recruitment

The objective of the trial is to evaluating the feasibility of dose increase by a boost of curietherapy in PDR (at least 40 Gy on D95) associated to extern radiotherapy (34 Gy) in intermediate risk in prostate cancer.

Inclusion Criteria:

• Age ≥ 50 years and ≤ 75 years
• Life expectancy >10 years
• Localized prostatic adenocarcinoma and histologically proven
• Intermediate risk cancer(T2b or PSA between 10 and 20 or Gleason = 7(3+4) according to Amico criteria
• Metastasis or pelvic pathologic ganglion (≥ 10 mm) absence
• OMS < 2
• No previous treatment by radiotherapy and/or curietherapy
• Hormonotherapy authorized before and during the study
• Rectal or uretero-vesical pathology
• Signed informed consent
• Social security system affiliation
• Individual deprived of liberty or placed under the authority of a tutor.
• No anesthesia contraindication

Exclusion Criteria:

• Adenocarcinoma not histologically proven
• Metastases presence
• Pathological nodes presence(≥ 10 mm)
• Prior prostate endoscopic resection
• history of other malignancy except for appropriately treated superficial basal cell skin cancer
• Medical contraindications to anesthesia
• Patients with uncontrolled psychiatric disease or medical disease incompatible with the protocol
• Impossibility to respect the medical follow-up of the protocol for geographical, social or psychic reasons